1. <optgroup id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></optgroup>
    <cite id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></cite>
      1. <legend id="wrmvh"></legend>

        <ol id="wrmvh"></ol>

          1. <strong id="wrmvh"></strong>
          2. <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <optgroup id="wrmvh"></optgroup>
            <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <span id="wrmvh"><sup id="wrmvh"><object id="wrmvh"></object></sup></span>
            1. <span id="wrmvh"><video id="wrmvh"></video></span>
              <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
              <strong id="wrmvh"></strong>
              <legend id="wrmvh"><i id="wrmvh"></i></legend>
              1. <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
                1.  
                   
                   
                   
                   
                  臨床PI
                  虞先濬 教授
                  教授,博士生導師
                  E-mail: yuxianjun88@hotmail.com
                   

                  復旦大學附屬腫瘤醫院副院長,上海市胰腺腫瘤研究所所長,復旦大學胰腺腫瘤研究所所長,中國抗癌協會胰腺癌專業委員會候任主任委員,CSPAC中國胰腺癌多學科協作組組長,中華醫學會外科學分會胰腺外科學組委員,中國醫師協會胰腺病學專業委員會、中國臨床腫瘤學會(CSCO)胰腺癌專家委員會常務委員,香港中文大學研究生院External Examiner,美國外科醫師學院Fellow(FACS),Cancer Letters中國上海編輯部執行主任,Cancer Letters編委等多本國際著名雜志編委/特約審稿專家。  

                  長期致力于胰腺癌臨床-基礎轉化研究,針對如何提升胰腺癌外科綜合治療水平,進而提高患者的長期生存這一問題,開展了系統的、逐步遞進的應用基礎和轉化醫學研究。獲得國家自然科學基金委杰出青年基金,入選國家科技部中青年科技創新領軍人才,上海市領軍人才和上海市優秀學術/技術帶頭人計劃,曾獲得國際胰腺病學會Outstanding Achievement in Pancreatology大獎,上海工匠、上海市五一勞動獎章獲得者。既往主持國家自然基金中德國際合作項目1項、面上項目3項,省部級項目12項;近5年以通訊作者(含共同)在J Clin Oncol、Gut、Ann Surg、Cell Res、Clin Cancer Res、Cancer Res等權威/主流期刊發表SCI論文150余篇,總IF>500分,單篇論著最高IF:28.2分。作為第一發明人獲得5項國家實用新型專利、上海市優秀發明選拔賽“金獎”。研究成果受到國內外同行認可,已被納入多部國際、國內胰腺腫瘤臨床指南/共識,指導臨床實踐。


                  研究領域:

                    1.發明“胰腸吻合”新方法,減少胰瘺,提高了手術安全性;
                    2.發明 5 項專用手術器械,協助深部淋巴結銳性清掃,使局部復發率降低 30%,提高了手術根治性;
                    3.發現胰腺癌“手術不獲益”亞群,施行術前個體化干預,提高了手術有效性;
                    4.首次提出基于間質比例的胰腺癌個體化化療策略,指導臨床實踐; 
                          5.發現胰腺惡性腫瘤增殖轉移特性,兩次創新改良國際臨床分期指南,發出“中國好聲音”。


                  研究團隊:



                  代表性論著:

                  1. Liang C., Shi S., Qin Y., Meng Q., Hua J., Hu Q., Ji S., Zhang B., Xu J., Yu X. J.* Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut, 2019.
                  2. Liang C., Xu J., Meng Q., Zhang B., Liu J., Hua J., Zhang Y., Shi S.*, Yu X.* TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Autophagy, 2019; 1-15.
                  3. Shi S., Hua J., Liang C., Meng Q., Liang D., Xu J., Ni Q., Yu X*. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. Ann Surg, 2019; 269(5): 944-950.
                  4. Zhang Y., Xu J., Hua J., Liu J., Liang C., Meng Q., Wei M., Zhang B., Yu X.*, Shi S*. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer, 2019; 7(1): 233.
                  5. Liang C., Shi S., Liu M., Qin Y., Meng Q., Hua J., Ji S., Zhang Y., Yang J., Xu J., Ni Q., Li M.*, Yu X*. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Cancer Res, 2019; 79(1): 133-145.
                  6. Shi S., Liang C., Xu J., Meng Q., Hua J., Yang X., Ni Q., Yu X*. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Ann Surg, 2018.
                  7. Meng Q., Shi S., Liang C., Liang D., Hua J., Zhang B., Xu J., Yu X*. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3beta/Snail signaling. Oncogene, 2018; 37(44): 5843-5857.
                  8. Luo G., Liu C., Guo M., Cheng H., Lu Y., Jin K., Liu L., Long J., Xu J., Lu R., Ni Q., Yu X*. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg, 2017; 265(4): 800-805.
                  9. Luo G., Javed A., Strosberg J. R., Jin K., Zhang Y., Liu C., Xu J., Soares K., Weiss M. J., Zheng L., Wolfgang C. L., Cives M., Wong J., Wang W., Sun J., Shao C., Wang W., Tan H., Li J., Ni Q., Shen L., Chen M., He J., Chen J.*, Yu X.* Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol, 2017; 35(3): 274-280.
                  10. Ji S., Qin Y., Liang C., Huang R., Shi S., Liu J., Jin K., Liang D., Xu W., Zhang B., Liu L., Liu C., Xu J., Ni Q., Chiao P. J., Li M., Yu X*. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. Clin Cancer Res, 2016 Aug 1; 22(15): 3950-60.
                  11. Wang W. Q., Liu L., Xu H. X., Wu C. T., Xiang J. F., Xu J., Liu C., Long J., Ni Q. X., Yu X. J*. Intratumoral infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br J Surg, 2016.
                  12. Ji S., Qin Y., Shi S., Liu X., Hu H., Zhou H., Gao J., Zhang B., Xu W., Liu J., Liang D., Liu L., Liu C., Long J., Zhou H., Chiao P. J., Xu J., Ni Q., Gao D., Yu X*. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res, 2015; 25(5): 561-573.
                  13. Yao W., Ji S., Qin Y., Yang J., Xu J., Zhang B., Xu W., Liu J., Shi S., Liu L., Liu C., Long J., Ni Q., Li M., Yu X*. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1alpha axis. Mol Cancer, 2014; 13187.
                  14. Xu H. X., Chen T., Wang W. Q., Wu C. T., Liu C., Long J., Xu J., Zhang Y. J., Chen R. H., Liu L., Yu X. J*. Metabolic tumour burden assessed by (1)(8)F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging, 2014; 41(6): 1093-1102.
                  15. Liu L., Xu H. X., Wang W. Q., Wu C. T., Chen T., Qin Y., Liu C., Xu J., Long J., Zhang B., Xu Y. F., Ni Q. X., Li M., Yu X. J*. Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene, 2014; 33(21): 2728-2736.
                   
                  復旦大學腫瘤研究所 通訊地址: 東安路270號2號樓1312室 64175590-5312 Email:fuci2012@126.com
                  Copyright 2013 shca.org.cn All rights reserved. 復旦大學腫瘤研究所 版權所有
                  小草在线观看视频播放免费 青草青青手机在线视频免费观看| 日本黄区免费| 小草社区可信吗| 日本亚洲欧洲无免费码在线| yy4080影视觉影院青苹果| 西瓜视频| 嫩草的香味一草民影院| 东阳六石东方伊甸园| 嫩草的香味中文| 宅男天堂百度云提取码| 嫩草的香味迅雷在线观看|